This was further validated by reduced upregulation of surface MHC II and of the costimulatory CD86 molecule on PU.1-depleted TIS compared to matched lymphoma cells with a control shRNA (Fig. 7b; see Supplementary Fig. 9a for no significant impact on MHC I). The gene discussed is CD86; the disease is lymphoma.